Prescribing information

 

Cosentyx is indicated for the treatment of: moderate to severe plaque psoriasis in adults who are candidates for systemic therapy; active psoriatic arthritis in adult patients, alone or in combination with MTX, when the response to previous DMARD therapy has been inadequate; active ankylosing spondylitis in adults who have responded inadequately to conventional therapy; active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated CRP and/or MRI evidence in adults who have responded inadequately to NSAIDs.

Explore our webinars from expert dermatology speakers

If you or your colleagues weren’t able to join our webinars, recordings can be found below. We’ll continue to grow the collection, so keep checking back!

New for 2021

placeholder thumbnail of video

 

Joint clinics: combining dermatology and rheumatology care within your Trust

Watch UK-based rheumatology and dermatology experts Professor Miriam Wittmann and Dr Helena Marzo-Ortega discuss the importance of joint plaque psoriasis (PsO) and psoriatic arthritis (PsA) clinics and offer perspectives on how joint dermatology–rheumatology clinics can be established within a Trust, and what benefits they can offer. They then further discuss their experiences when setting up a joint clinic.

Click here to watch the full video

Thumbnail image of video

 

Treating plaque psoriasis (PsO) and psoriatic arthritis (PsA) patients with multiple manifestations

Watch Dr Christos Kasparis and Professor Laura Coates discuss the management of PsO and PsA patients with multiple manifestations and offer perspectives on the importance of timely screening and treating appropriate patients early with the correct biologic. The opinion leaders also describe the complete Cosentyx (secukinumab) approach, discussing clinical trial evidence from MAXIMISE for PsA, and nail and scalp data.

Click here to watch the full video

 

Best of 2020

 

 

Click here for Cosentyx®(secukinumab) prescribing information

Dermatology 2020: A virtual reality

In this virtual meeting series, a number of key opinion leaders gathered to discuss hot topics in dermatology, including the latest data in psoriasis. Hear from Dr Amy Foulkes on why you should watch more.

“Watch out for the latest real world evidence data from the BADBIR group, data from the EXCEED head-to-head trial, the updated BAD guidelines for 2020…”

Register to watch the full video

 

 

Click here for Cosentyx®(secukinumab) prescribing information

Webinar highlights: Dermatology clinics in a virtual era

The COVID-19 pandemic has transformed dermatology services – but where do we go from here? In this webinar highlights video, Dr Laura Savage explores how we can embrace technology to continue making positive changes for our patients.

“Many patients can be managed less frequently, they can be managed remotely or they can be managed with advice and guidance from the GP. That’s only going to continue to improve our capacity and reduces patient inconvenience.”

Register to watch the full video

 

 

 

Click here for Cosentyx®(secukinumab) prescribing information

Webinar highlights: Real-world evidence in clinical decision making

What really matters when making clinical decisions in psoriasis? In the highlights of her webinar, hear Dr Laura Savage discuss how real-world evidence can be used in clinical practice and how it could help inform treatment choices.

“…real-world evidence really is the missing piece of this jigsaw where we really want to try to use that to get an understanding of what’s going to happen in the clinical setting.”

Register to watch the full video

 

BAD, British association of dermatology; BADBIR, British Association of Dermatologists Biologics and Immunomodulators Register; DMARD, disease-modifying anti-rheumatic drug; NSAID, non-steroidal anti-inflammatory drug; MTX, methotrexate.

Rate this content: 
No votes yet
UK | June 2021 | 131427
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]